Charleston Laboratories, Inc. announces formation of U.S. commercial subsidiary.

Charleston Laboratories, Inc. announces the formation of Õlas Pharma, Inc., a wholly owned U.S. subsidiary established to conduct commercialization activities for Charleston Laboratories’ pipeline of products that address significant patient needs such as Opioid-Induced Nausea and Vomiting (OINV) and Migraine-Induced Nausea and Vomiting (MINV), including co-promotion activities under its collaboration with Daiichi Sankyo.

“The creation of a formal commercial presence has always been a part of Charleston Laboratories’ growth strategy and it is extremely gratifying to reflect on the hard work and successes that have made this a reality. The formation of Õlas Pharma lays the groundwork for our direct involvement in commercialization of our robust pipeline of drug candidates,” said Mr. Paul Bosse, President and Chief Executive Officer at Charleston Laboratories. “We are focused on developing novel products for the treatment of pain and related burdensome side effects to improve the lives of patients suffering with pain and their families. In addition, we are continuously evaluating outside opportunities that provide synergy to our areas of therapeutic focus.”

(Source: PR Newswire)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!